Cargando…

Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity

[Image: see text] ATP-binding cassette (ABC)-transporters protect tissues by pumping their substrates out of the cells in many physiological barriers, such as the blood–brain barrier, intestine, liver, and kidney. These substrates include various endogenous metabolites, but, in addition, ABC transpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Feng, Ghemtio, Leo, Grazhdankin, Evgeni, Wipf, Peter, Xhaard, Henri, Kidron, Heidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497665/
https://www.ncbi.nlm.nih.gov/pubmed/32496785
http://dx.doi.org/10.1021/acs.molpharmaceut.0c00155
_version_ 1783583363450273792
author Deng, Feng
Ghemtio, Leo
Grazhdankin, Evgeni
Wipf, Peter
Xhaard, Henri
Kidron, Heidi
author_facet Deng, Feng
Ghemtio, Leo
Grazhdankin, Evgeni
Wipf, Peter
Xhaard, Henri
Kidron, Heidi
author_sort Deng, Feng
collection PubMed
description [Image: see text] ATP-binding cassette (ABC)-transporters protect tissues by pumping their substrates out of the cells in many physiological barriers, such as the blood–brain barrier, intestine, liver, and kidney. These substrates include various endogenous metabolites, but, in addition, ABC transporters recognize a wide range of compounds, therefore affecting the disposition and elimination of clinically used drugs and their metabolites. Although numerous ABC-transporter inhibitors are known, the underlying mechanism of inhibition is not well characterized. The aim of this study is to deepen our understanding of transporter inhibition by studying the molecular basis of ligand recognition. In the current work, we compared the effect of 44 compounds on the active transport mediated by three ABC transporters: breast cancer resistance protein (BCRP and ABCG2), multidrug-resistance associated protein (MRP2 and ABCC2), and P-glycoprotein (P-gp and ABCB1). Eight compounds were strong inhibitors of all three transporters, while the activity of 36 compounds was transporter-specific. Of the tested compounds, 39, 25, and 11 were considered as strong inhibitors, while 1, 4, and 11 compounds were inactive against BCRP, MRP2, and P-gp, respectively. In addition, six transport-enhancing stimulators were observed for P-gp. In order to understand the observed selectivity, we compared the surface properties of binding cavities in the transporters and performed structure–activity analysis and computational docking of the compounds to known binding sites in the transmembrane domains and nucleotide-binding domains. Based on the results, the studied compounds are more likely to interact with the transmembrane domain than the nucleotide-binding domain. Additionally, the surface properties of the substrate binding site in the transmembrane domains of the three transporters were in line with the observed selectivity. Because of the high activity toward BCRP, we lacked the dynamic range needed to draw conclusions on favorable interactions; however, we identified amino acids in both P-gp and MRP2 that appear to be important for ligand recognition.
format Online
Article
Text
id pubmed-7497665
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-74976652020-09-18 Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity Deng, Feng Ghemtio, Leo Grazhdankin, Evgeni Wipf, Peter Xhaard, Henri Kidron, Heidi Mol Pharm [Image: see text] ATP-binding cassette (ABC)-transporters protect tissues by pumping their substrates out of the cells in many physiological barriers, such as the blood–brain barrier, intestine, liver, and kidney. These substrates include various endogenous metabolites, but, in addition, ABC transporters recognize a wide range of compounds, therefore affecting the disposition and elimination of clinically used drugs and their metabolites. Although numerous ABC-transporter inhibitors are known, the underlying mechanism of inhibition is not well characterized. The aim of this study is to deepen our understanding of transporter inhibition by studying the molecular basis of ligand recognition. In the current work, we compared the effect of 44 compounds on the active transport mediated by three ABC transporters: breast cancer resistance protein (BCRP and ABCG2), multidrug-resistance associated protein (MRP2 and ABCC2), and P-glycoprotein (P-gp and ABCB1). Eight compounds were strong inhibitors of all three transporters, while the activity of 36 compounds was transporter-specific. Of the tested compounds, 39, 25, and 11 were considered as strong inhibitors, while 1, 4, and 11 compounds were inactive against BCRP, MRP2, and P-gp, respectively. In addition, six transport-enhancing stimulators were observed for P-gp. In order to understand the observed selectivity, we compared the surface properties of binding cavities in the transporters and performed structure–activity analysis and computational docking of the compounds to known binding sites in the transmembrane domains and nucleotide-binding domains. Based on the results, the studied compounds are more likely to interact with the transmembrane domain than the nucleotide-binding domain. Additionally, the surface properties of the substrate binding site in the transmembrane domains of the three transporters were in line with the observed selectivity. Because of the high activity toward BCRP, we lacked the dynamic range needed to draw conclusions on favorable interactions; however, we identified amino acids in both P-gp and MRP2 that appear to be important for ligand recognition. American Chemical Society 2020-06-04 2020-07-06 /pmc/articles/PMC7497665/ /pubmed/32496785 http://dx.doi.org/10.1021/acs.molpharmaceut.0c00155 Text en Copyright © 2020 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
spellingShingle Deng, Feng
Ghemtio, Leo
Grazhdankin, Evgeni
Wipf, Peter
Xhaard, Henri
Kidron, Heidi
Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity
title Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity
title_full Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity
title_fullStr Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity
title_full_unstemmed Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity
title_short Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity
title_sort binding site interactions of modulators of breast cancer resistance protein, multidrug resistance-associated protein 2, and p-glycoprotein activity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497665/
https://www.ncbi.nlm.nih.gov/pubmed/32496785
http://dx.doi.org/10.1021/acs.molpharmaceut.0c00155
work_keys_str_mv AT dengfeng bindingsiteinteractionsofmodulatorsofbreastcancerresistanceproteinmultidrugresistanceassociatedprotein2andpglycoproteinactivity
AT ghemtioleo bindingsiteinteractionsofmodulatorsofbreastcancerresistanceproteinmultidrugresistanceassociatedprotein2andpglycoproteinactivity
AT grazhdankinevgeni bindingsiteinteractionsofmodulatorsofbreastcancerresistanceproteinmultidrugresistanceassociatedprotein2andpglycoproteinactivity
AT wipfpeter bindingsiteinteractionsofmodulatorsofbreastcancerresistanceproteinmultidrugresistanceassociatedprotein2andpglycoproteinactivity
AT xhaardhenri bindingsiteinteractionsofmodulatorsofbreastcancerresistanceproteinmultidrugresistanceassociatedprotein2andpglycoproteinactivity
AT kidronheidi bindingsiteinteractionsofmodulatorsofbreastcancerresistanceproteinmultidrugresistanceassociatedprotein2andpglycoproteinactivity